[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.171.146.16. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 10,988
Citations 0
Medical News & Perspectives
July 31, 2019

Weighing the Risks and Rewards of Peanut Oral Immunotherapy

JAMA. 2019;322(7):596-598. doi:10.1001/jama.2019.9142

For the millions of people with peanut allergies, oral immunotherapy offers the possibility of fewer allergic reactions and a life lived with far less anxiety. That life could be on the horizon: the US Food and Drug Administration (FDA) is expected to rule on the first peanut desensitization product, Aimmune Therapeutics’ biologic, AR101, later this year.

×